Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with classical Hodgkin lymphoma (cHL), suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL.
[Blood Advances]
7992332
{7992332:AAAAAAAA}
apa
50
1
166446
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
